U.S. Recommends ‘Pause’ for Johnson & Johnson Vaccine Over Blood Clot Reports

About This Source - Bloomberg QuickTake: Now

Bloomberg L.P. is a privately held financial, software, data, and media company headquartered in Midtown Manhattan, New York City.

It was founded by Michael Bloomberg in 1981, with the help of Thomas Secunda, Duncan MacMillan, Charles Zegar, and a 12% ownership investment by Merrill Lynch.

Recent from Bloomberg QuickTake: Now:

  • De Blasio to Cuomo: ‘Get the Hell Out’
  • Tokyo Hits Record of Over 5,000 Cases as Olympics Closing Nears
  • Belarus Runner Showed Japanese Police Plea for Help on Her Phone
  • Bloomberg Quicktake: Now published this video item, entitled “U.S. Recommends ‘Pause’ for Johnson & Johnson Vaccine Over Blood Clot Reports” – below is their description.

    U.S. health officials called for an immediate pause in use of Johnson & Johnson’s single-dose Covid-19 vaccine after six women who received it developed a rare and severe form of blood clotting.

    The decision comes at a crucial juncture in the U.S. vaccination effort, which has been gaining speed in recent weeks at the same time that a worsening outbreak driven by coronavirus variants is gripping the upper Midwest. And it is likely to heighten worry about vaccines around the world after similar issues caused delays in distribution of AstraZeneca Plc’s shot.

    A type of brain blood clot called cerebral venous sinus thrombosis was seen with low levels of blood platelets in the women, who were all between the ages of 18 and 48, the U.S. Centers for Disease Control and Prevention and Food and Drug Administration said on Tuesday in a joint statement.

    “We are recommending a pause in the use of this vaccine out of an abundance of caution,” the CDC and the FDA said in the statement. “This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.”

    More than 6.8 million doses of the J&J vaccine have been administered in the U.S. through Monday, the agencies said.

    The Biden administration has been seeking to accelerate vaccinations in recent weeks as new coronavirus variants heighten the risk that the pandemic could drag on. Officials expect 100 million doses of J&J’s vaccine to help cover all adults near the end of May.

    The prospect that the pause could disrupt the U.S. economic recovery weighed on financial markets on Tuesday, with futures trading indicating that the stock market was likely to open lower. Contracts tied to the S&P 500 were down roughly 0.23%.

    J&J representatives didn’t immediately respond to a request for comment. The shares fell 3% in premarket U.S. trading.


    The decision could increase vaccine hesitancy, which is seen as a significant obstacle for health policy makers as they attempt to broaden immunizations. The J&J shot has been popular due to its single dose — vaccines made by Pfizer Inc.-BioNTech SE and Moderna Inc. require two doses spaced several weeks apart.

    Many of the J&J doses in the U.S. have been targeted to harder-to-reach populations through the federal government’s distribution program that targets pharmacies, federally qualified health centers and other locations.

    The CDC will convene a meeting Wednesday of its Advisory Committee on Immunization Practices to review the cases and assess their potential significance. The FDA will review the CDC assessment as it also investigates these cases, according to the statement.

    The recommended pause may also further complicate the global vaccination push, coming just weeks after a vaccine relying on a similar approach and developed by AstraZeneca and the University of Oxford raised similar concerns in Europe. Clotting fears have prompted many countries to impose age restrictions on use of the Astra vaccine, which was co-developed with the University of Oxford.

    J&J has recently begun shipments to the European Union. The bloc’s drugs regulator, the European Medicines Agency, didn’t immediately respond to a request for comment.

    The EMA has previously said that it is assessing blood clots in people who received the J&J vaccine, after four serious cases of unusual clots accompanied by low blood platelets, one of which was fatal, emerged.

    On Friday afternoon, FDA spokesperson Abby Capobianco said in an emailed statement that the agency hadn’t found a causal relationship with between the J&J vaccine and the six cases of thromboembolic events, and was continuing its assessment of the cases.

    “Our analysis of the data will inform the potential need for regulatory action,” she said.

    Asked Monday if further analysis had determined a casual relationship, the FDA declined to comment.

    Bloomberg Quicktake: Now YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    In This Story: AstraZeneca

    AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.

    3 Recent Items: AstraZeneca

  • More Queenslanders can get a COVID vaccine | 7NEWS
  • Hunter region forced into lockdown, woman dies after AstraZeneca vaccine | 9 News Australia
  • IN FULL: NSW authorities announce five deaths and 262 new cases of COVID-19 | ABC News
  • In This Story: BioNTech

    BioNTech SE (NASDAQ: BNTX) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.

    5 Recent Items: BioNTech

  • Why is Germany’s CureVac vaccine just 48% effective? | Covid-19 Special
  • UK health authorities recommend Covid jabs for 16- and 17-year-olds
  • BREAKING: All 16 and 17-year-olds to be offered COVID-19 jabs
  • LIVE: ‘Very Real Fourth Wave’ Presses FDA to Fully Approve Covid Shots | Top News
  • U.S. Covid Surge Steps Up Pressure on FDA to Approve Pfizer Vaccine
  • In This Story: COVID-19

    Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.

    Symptoms of coronavirus

    The main symptoms of coronavirus are:

    • a persistent new cough (non productive, dry)
    • a high temperature (e.g. head feels warm to the touch)
    • shortness of breath (if this is abnormal for the individual, or increased)

    Latest News about Covid-19

    Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.

    5 Recent Items: COVID-19

  • De Blasio to Cuomo: ‘Get the Hell Out’
  • Trudeau looking into making COVID-19 vaccinations mandatory for federal workers
  • US pole vaulter wins gold as COVID-19 cases surge in Tokyo
  • COVID crisis leaves thousands unemployed, homeless in Bangladesh
  • Tokyo Hits Record of Over 5,000 Cases as Olympics Closing Nears
  • In This Story: Moderna

    Moderna is an American biotechnology company based in Cambridge, Massachusetts that focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.

    CEO: Stéphane Bancel (2011–)

    Stock ticker: (NASDAQ:MRNA)

    5 Recent Items: Moderna

  • Moderna says vaccine 93% effective after 6 months
  • Why is Germany’s CureVac vaccine just 48% effective? | Covid-19 Special
  • Moderna Says Vaccine Is 93% Effective Against Covid After Six Months
  • Moderna beats estimates and releases positive vaccine data
  • Moderna CEO on its latest vaccine efficacy data
  • Leave a Comment